Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Myers
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 1.66
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -13.54
Financials
Net Income
$-5.46MEBITDA
$-5.54MFree Cash Flow
$-3.21MEPS (diluted)
$-2.72Shares Outstanding (diluted)
2.01M+455323.4%Operating Expenses
$5.54MCash & Debt
$10.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-15.80M | $-10.63 |
| 2024 | $0.00 | $-8.96M | $-2352.81 |
| 2023 | $0.00 | $-8.69M | $-11781.00 |
| 2022 | $0.00 | $-9.38M | $-11.42 |
| 2021 | $0.00 | $-21.46M | $-2490.26 |
| 2020 | $0.00 | $-2.10M | $-1290.96 |
| 2019 | $0.00 | $-1.56M | $-16307.00 |
| 2018 | $-280.0K | $15.32M | $-158862.00 |
| 2017 | $0.00 | $10.17M | $-257489.00 |
| 2016 | $-280.0K | $15.32M | $-160847.00 |
| 2015 | $0.00 | $-2.62M | $-1.23 |
Valuation
QNRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
…uoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, includin…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – Receives U.S. Notice of Allowance for a Patent Covering a Combination Treatment for Netherton Syndrome – Submits First-Ever IND for Peeling Skin Syndrome; FDA Clearance Received Subseque
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-1.53 per share
Typical surprise -5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.90 vs $-1.83miss
- Thu, May 7$-1.77 vs $-1.80beat
- Thu, Mar 26$-14.80 vs $-6.42miss
- Thu, Nov 6$-6.71 vs $-6.36miss
- Thu, Aug 7$-6.28 vs $-6.83beat
- Tue, May 13$-6.50 vs $-3.85miss
Estimates and results for QNRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QNRX officers and directors.
- Bought
- $3.1m
- Sold
- $217
38 trades
1 trade
- Carter Denise P.bought
- Carter Denise P.bought
- Myers Michaelbought
- Myers Michaelbought
- Lawlor Sally Bridgetbought
- Lawlor Sally Bridgetbought
- Culverwell Anthony Jamesbought
- Culverwell Anthony Jamesbought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in QNRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.